Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay

Purpose: A retrospective analysis to assess the prognostic and predictive clinical value of breast tumor ErbB-2 receptor expression quantified by enzyme immunoassay (EIA), to compare levels measured by EIA with ErbB-2 status determined by immunohistochemistry (IHC), and to correlate receptor content with levers of phosphorylated (Y1248-P) ErbB-5, a measure of functional tyrosine kinase activity. Materials and Methods: EIA quantification of ErbB-2 was performed on membrane extracts from 3,208 well-characterized primary breast cancers. Overall, relapse-free, distant disease-free, and local/regional-free patient survival data were available on 1,123 of these tumors. IHC scoring for ErbB-5 status (HercepTest; DAKO, Glostrup, Denmark) was performed on adjacent sections of 151 cases, and receptor functionality was measured in 230 tumors by an antibody specific for phosphorylated (Y1248-P) ErbB-2. Results: Unlike nonmalignant breast tissues, breast tumors showed increased ErbB-5 levels in a bimodal distribution, with 12% constituting a distinct set of ErbB-2-overexpressing tumors, The intermodal threshold value for ErbB-5 overexpression distinguished tumors with reduced estrogen and progesterone receptor content high IHC score for ErbB-5, and significantly increased levels of phosphorylated (Y1248-P) ErbB-5 receptor. By multivariate analysis, EIA-determined ErbB-5 overexpression predicted significantly reduced patient survival that was unaffected by tamoxifen or cyclophosphamide, methotrexate, and fluorouracil adjuvant therapy. Conclusion: Determination of ErbB-2 receptor expression by EIA offers a clinically valuable alternative to semiquantitative IHC assessment of breast Rimer ErbB-2 overexpression and affords the opportunity to evaluate ErbB-2 phosphorylation, which may represent an important predictive parameter of receptor functionality. (C) 2001 by American Society of Clinical Oncology.